SPOTLIGHT -
The Potential Costs of Healthcare Price Transparency
A proposed policy calling for hospitals to publicly disclose negotiated prices charged for services is drawing ire from some hospitals and insurance companies.
Read More
2019 Asembia Specialty Pharmacy Summit: 3 Key Takeaways
Asembia offers broad coverage across specialty pharmacy.
Specialty Pharmacy’s Role in Improving Orphan Drug Channels
Pharmacists are in a unique position to improve orphan drug and precision medicine channels.
Considering a Post-Rebate Future in Specialty Pharmacy
Experts offer their thoughts on what the specialty pharmacy industry will look like over the next year.
How Mergers Change Specialty Pharmacy
As the healthcare landscape continues to change at a rapid pace, drug manufacturers need to take a long, hard look at their marketing and commercialization options.
How Immuno-Oncology Biomarkers Are Changing Cancer Care
With so many new immunotherapy treatments on the horizon, pharmacists need to understand the ins and outs of immuno-oncology biomarkers to best serve their patients.
3 Ways Insurers Can Help Promote Biosimilar Adoption
The FDA Commissioner says that insurers can help biosimilar adoption by taking short-term financial losses over long-term drug savings. What else should they be doing?
Understanding Both Sides of the Copay Accumulator Debate
At the 2019 Asembia Specialty Pharmacy Summit, Cardinal Health’s Bruce Feinberg articulates the pros and cons of copay accumulator programs.
UnitedHealthcare to Expand Consumer Drug Rebates
OptumRx will expand its drug discounts to employer-sponsored health plans starting next year. Here’s what the move means for healthcare.
Calls for “Structural Policy Changes” for Biosimilars Market
The Biosimilars Forum, in partnership with Medicines for Europe, says the U.S. can look to European policy directives to advance the biosimilars market.
FDA Issues Biosimilar Naming Guidance
The FDA issued a lengthy statement on biosimilar naming conventions-but industry groups worry it could disincentivize biosimilar development.
The Fight to End Misleading Info on Biosimilars
Industry groups are calling for clear FDA guidance on language used by biologic originators to protect market share.
Genetic Testing in Treatment Decision Making Goes Mainstream
The technology is improving rapidly, becoming not only more accessible but much, much cheaper.
The Biggest Obstacle to Cancer Biosimilar Development
Biosimilar drugs are poised to transform the cancer drug market-so why is uptake so slow?
3 Creative Ways Biologic Innovators Are Protecting Their Turf
As more biosimilar agents are approved by the FDA, biologic manufacturers are looking for unique ways to hold on to market share.
Top 2 Myths About Biosimilars
Biosimilar adoption is not happening as fast as once expected-will fears about future growth hold the market back?
Three Ways the Government Shutdown is Affecting Biosimilar Development
The partial government shutdown is affecting the country in many ways-but how is it interfering with biosimilar development?
Will Threats to the ACA Derail Biosimilar Development?
With a new ruling against the Affordable Care Act (ACA), many worry about the fate of the biosimilar market. But will it be as detrimental as feared?
Top 3 Biosimilar Developments of 2018
2018 was meant to be a big year for the biosimilar market-but were developments as big as hoped? Find out.
Social Determinants of Health Play Growing Role in Hospital, Payer Strategies
Evidence grows that these nonclinical factors have a large influence on patient outcomes. Here’s what hospitals and payers can do about it.
How Machine Learning is Changing Mental Health
Machine learning is helping scientists better understand the development of mental health conditions-and the best ways to help treat them.
Three COPD Risk Factors Providers Need to Tell Patients About
COPD is a chronic, progressive disorder that can lead to early death. Here are some ways to help mitigate the risk of developing this debilitating disorder.
Three Types of Apps Changing Mental Health Treatment
Your favorite app store is likely filled with many mental health offerings. But what can they really offer?
Two Reasons Why Payers Love Biosimilars
With all eyes on drug prices, payers are looking to biosimilar agents to cut costs-and improve patient outcomes.
Top Barriers to Biosimilar Approval and Adoption in the U.S.
The biosimilar market is flourishing in Europe-why aren’t we seeing similar gains in the U.S.?
Formulary Management for Biosimilars: 4 Payer Challenges
Biosimilar agents can help healthcare organizations offer patients more options for their care. So, what’s stopping payers from immediately adding them to their formularies?
Three Ways Biosimilars Can Play a Role in Value-Based Care
As healthcare organizations move toward value-based models of reimbursement, high drug prices can sometimes get in the way of optimal care. Here are three ways that biosimilars may help.
Mental Health First Aid Training: 4 Reasons Health Orgs Should Participate
This evidence-based training program can help communities better understand how to connect, not correct, individuals who may be struggling with mental health issues.
Two Ways Med Adherence Curbs Hospital Visits in Schizophrenia
It can be challenging for patients with schizophrenia to keep to a medication regimen-here are the reasons why it’s important to invest in strategies to help them stay compliant.
Top Public Health Issues Impacting Healthcare Organizations
Healthcare organizations can improve care and lower costs-across the board-by paying careful attention to the public health issues affecting their communities.